ZEPOSIA
Drug
Celgene Corporation
Total Payments
$56.2M
Transactions
214,888
Doctors
20,857
Companies
2
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $10.1M | 38,020 | 10,134 |
| 2023 | $10.1M | 73,980 | 12,663 |
| 2022 | $19.3M | 65,790 | 12,071 |
| 2021 | $13.9M | 30,072 | 9,326 |
| 2020 | $2.9M | 7,026 | 2,014 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $34.2M | 1,411 | 60.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $14.0M | 5,995 | 24.9% |
| Food and Beverage | $4.4M | 201,081 | 7.8% |
| Consulting Fee | $1.7M | 688 | 3.0% |
| Travel and Lodging | $1.6M | 4,216 | 2.9% |
| Space rental or facility fees (teaching hospital only) | $178,250 | 82 | 0.3% |
| Education | $150,314 | 1,412 | 0.3% |
| Honoraria | $8,000 | 2 | 0.0% |
| Grant | $2,500 | 1 | 0.0% |
Payments by Type
Research
$34.2M
1,411 transactions
General
$22.0M
213,477 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A Phase 1, Randomized, Double-blind, Placebo- and - A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Effect of Ozanimod on Pressor Response to Oral Tyramine in Healthy Adult Subjects | Celgene Corporation | $9.0M | 0 |
| A Phase 1, Randomized, Double-blind, Placebo- and | Celgene Corporation | $6.3M | 0 |
| A Phase 4, Global, Prospective, Open label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants with Moderate to Severe Ulcerative Colitis in Clinical Practice | E.R. Squibb & Sons, L.L.C. | $3.6M | 0 |
| PhIII Yellowstone Induction Study # 1 OZANIMOD in Moderate to Severe CD (RPC01-3201) | Celgene Corporation | $1.6M | 1 |
| A Phase 1, Open-Label, Single Dose Study to Assess | Celgene Corporation | $1.0M | 0 |
| PhIII Yellowstone Induction Study # 2 OZANIMOD in Moderate to Severe CD (RPC01-3202) | Celgene Corporation | $995,299 | 3 |
| A Phase 3, Multicenter, Open-Label Extension Study | Celgene Corporation | $847,151 | 1 |
| Ph III Yellowstone CD OLE (RPC01-3204) - A Phase 3, Multicenter, Open-Label Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn s Disease | Celgene Corporation | $809,938 | 0 |
| Induction Study #1 - A Phase 3, Multicenter, Rando | Celgene Corporation | $804,773 | 0 |
| Zeposia Covid-19 VAcciNe Trial (Z-CAN) | E.R. Squibb & Sons, L.L.C. | $750,000 | 0 |
| Induction Study #2 - A Phase 3, Multicenter, Rando | Celgene Corporation | $592,530 | 3 |
| Topographical Model of MS: Using Quantified Grey Matter and Spinal Cord Volume to Estimate Reserve Against Impact of Lesions | Celgene Corporation | $585,734 | 0 |
| Ph III Yellowstone CD Maintenance (RPC01-3203) - A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Oral Ozanimod as Maintenance Therapy for Moderately to Severely Active Crohn s Disease | Celgene Corporation | $522,671 | 0 |
| (RPC-1063-CP-005) Food Effect (Tyramine Challenge) | Celgene Corporation | $522,397 | 0 |
| Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease | Celgene Corporation | $482,758 | 2 |
| Anti-inflammatory properties of Ozanimod in the intestinal mucosa of IBD patients | Celgene Corporation | $469,850 | 0 |
| An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease | Celgene Corporation | $448,041 | 1 |
| An Open-label Study of Ozanimod in Moderate to Severe Ulcerative Colitis in Clinical Practice | E.R. Squibb & Sons, L.L.C. | $436,897 | 0 |
| UC Community Study | E.R. Squibb & Sons, L.L.C. | $379,667 | 0 |
| Characterization of scRNAseq profiles associated with ozanimod treatment and age in MS patients | E.R. Squibb & Sons, L.L.C. | $367,125 | 0 |
Top Doctors Receiving Payments for ZEPOSIA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Phila, PA | $34.3M | 1,590 |
| , MD | Gastroenterology | New York, NY | $307,597 | 485 |
| , MD | Gastroenterology | Oklahoma City, OK | $287,941 | 273 |
| , MD | Neurology | Des Moines, IA | $267,346 | 209 |
| , M.D | Neurology | Milwaukee, WI | $263,948 | 209 |
| , M.D | Gastroenterology | New York, NY | $260,967 | 253 |
| , MD | Internal Medicine | Colorado Springs, CO | $249,394 | 219 |
| , MD | Spinal Cord Injury Medicine | Lutherville, MD | $231,919 | 329 |
| , MD | Neurology | Audubon, NJ | $218,908 | 321 |
| , MD, MPH | Gastroenterology | Henderson, NV | $202,356 | 193 |
| , MD | Gastroenterology | Chicago, IL | $201,333 | 133 |
| , M.D | Gastroenterology | Maywood, IL | $195,281 | 145 |
| , MD | Neurology | Phoenix, AZ | $187,439 | 187 |
| , M.D | Neurology | Newport Beach, CA | $186,809 | 123 |
| Douglas Jeffery | — | Mooresville, NC | $179,604 | 153 |
| , M.D | Gastroenterology | White Sulphur Springs, WV | $179,312 | 218 |
| , M.D | Neurology | Washington, DC | $177,639 | 156 |
| , M.D | Neurology | Tampa, FL | $177,282 | 254 |
| , M.D | Neurology | Glen Burnie, MD | $172,697 | 257 |
| , M.D | Neuro-ophthalmology | Carlsbad, CA | $170,224 | 193 |
| , M.D | Gastroenterology | Coral Springs, FL | $166,984 | 184 |
| , M.D | Neurology | Staten Island, NY | $163,939 | 173 |
| , MD | Internal Medicine | Kansas City, KS | $159,261 | 222 |
| , D.O | Gastroenterology | Fort Sam Houston, TX | $154,900 | 155 |
| , MD | Gastroenterology | Charlotte, NC | $148,448 | 162 |
Ad
Manufacturing Companies
- Celgene Corporation $34.4M
- E.R. Squibb & Sons, L.L.C. $21.8M
Product Information
- Type Drug
- Total Payments $56.2M
- Total Doctors 20,857
- Transactions 214,888
About ZEPOSIA
ZEPOSIA is a drug associated with $56.2M in payments to 20,857 healthcare providers, recorded across 214,888 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2020 to 2024. In 2024, $10.1M was paid across 38,020 transactions to 10,134 doctors.
The most common payment nature for ZEPOSIA is "Unspecified" ($34.2M, 60.8% of total).
ZEPOSIA is associated with 20 research studies, including "A Phase 1, Randomized, Double-blind, Placebo- and - A Phase 1, Randomized, Double-blind, Placebo- and Positive-controlled Study to Evaluate the Effect of Ozanimod on Pressor Response to Oral Tyramine in Healthy Adult Subjects" ($9.0M).